# The Cooper Companies, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/The Cooper Companies, Inc).

## Overview

The Cooper Companies, Inc. is a U.S.-based medical device company organized around two businesses: CooperVision and CooperSurgical. CooperVision sells soft contact lenses and myopia-management products, while CooperSurgical supplies fertility, women’s health, and surgical products and services. The company serves customers in more than 130 countries and says its products and services positively affect over fifty million lives each year. Its business model combines recurring consumable demand in vision care with procedure-linked and clinic-based demand in fertility and women’s health.

## Products & services

• Soft contact lenses, including toric, multifocal and spherical lenses
• Myopia management lenses, including MiSight
• Surgical devices and related women’s health products
• Fertility solutions and reproductive health products
• Donor gametes and assisted reproduction services
• Cord blood and cord tissue storage services

- **CooperVision contact lenses** (68%) — Reusable and disposable soft contact lenses for vision correction, including specialty lenses for astigmatism and presbyopia.
- **Myopia management** (7%) — Pediatric lenses and related programs designed to slow the progression of myopia in children.
- **CooperSurgical fertility solutions** (12%) — Products and services used in assisted reproduction, including fertility clinic tools and donor gamete offerings.
- **CooperSurgical women’s health and surgical devices** (10%) — Devices and consumables used in gynecology, obstetrics, and related surgical procedures.
- **Storage and other services** (3%) — Cord blood and cord tissue storage and other ancillary services tied to reproductive health.

- Soft contact lenses, including toric, multifocal and spherical lenses
- Myopia management lenses, including MiSight
- Surgical devices and related women’s health products
- Fertility solutions and reproductive health products
- Donor gametes and assisted reproduction services
- Cord blood and cord tissue storage services

## Customers

CooperVision sells primarily to eye care professionals and the channels that serve them, including optometrists, ophthalmologists, opticians, optical chains, distributors, and mass merchandisers. Its products are bought because they are recurring consumables and because specialty lenses and myopia-management products address clinical needs that standard lenses do not. CooperSurgical sells to fertility clinics, hospitals, surgery centers, and women’s health practitioners through field sales teams, inside sales, and distributors. The company also reaches end consumers indirectly through donor gametes and storage services, where awareness and trust are important purchase drivers. Customer concentration is limited at the consolidated level, but management notes increasing consolidation among large customer groups and retail chains, which makes key accounts more important over time.

- **Eye care practitioners and optical chains** (primary) — Buy CooperVision lenses for fitting, dispensing, and repeat patient refills, especially specialty and premium silicone hydrogel products.
- **Distributors and retail channels** (primary) — Purchase and resell lenses in smaller countries and broader retail settings where Cooper uses channel partners to reach end users.
- **Fertility clinics** (primary) — Buy CooperSurgical fertility products, donor gametes, and related services to support assisted reproduction procedures.
- **Hospitals and surgery centers** (secondary) — Buy women’s health and surgical devices used in clinical procedures and inpatient or outpatient care.
- **Consumers and patients** (secondary) — Use myopia-management lenses, donor-related services, and storage offerings, often influenced by clinician recommendation and direct-to-consumer marketing.

- Optometrists and ophthalmologists buying contact lenses for patient fitting and repeat supply
- Optical chains and retail eye-care groups buying branded lenses at scale
- Distributors and mass merchandisers serving smaller markets and local practices
- Fertility clinics buying devices, consumables, and donor-related services
- Hospitals and surgery centers buying women’s health and surgical products
- Consumers using donor gametes or storage services through clinic channels

## Geography

Cooper sells products in over 130 countries, so its revenue base is broadly international rather than concentrated in one market. CooperVision reports three primary regions: the Americas, EMEA, and Asia Pacific, with the Americas and EMEA contributing the largest shares of segment sales in fiscal 2025. CooperSurgical distributes mainly from the United States and the Netherlands and also operates fertility and stem cell storage facilities in the United States, Canada, and Australia. The company’s manufacturing and distribution footprint is spread across multiple countries, including the United Kingdom, Belgium, Hungary, the United States, and smaller international sites, which helps support local service levels but also creates operational and regulatory complexity. Foreign exchange movements, local economic conditions, and country-specific regulatory approvals can materially affect both demand and supply.

- **Americas** (41%) — Estimated from CooperVision regional sales mix and company-wide global footprint.
- **EMEA** (39%) — Estimated from CooperVision regional sales mix and distribution/manufacturing footprint.
- **Asia Pacific** (20%) — Estimated from CooperVision regional sales mix and company disclosures.

- Sales are global, with products sold in more than 130 countries
- CooperVision’s main regions are the Americas, EMEA, and Asia Pacific
- CooperVision distributes from Belgium, Hungary, the UK, and the US
- CooperSurgical distributes mainly from the US and the Netherlands
- Fertility and storage facilities operate in the US, Canada, and Australia
- FX swings and local regulation affect both pricing and operating costs

## Strategy

Cooper’s strategy centers on expanding premium and specialty contact lenses, especially silicone hydrogel, toric, multifocal, and myopia-management products that support better clinical outcomes and higher customer loyalty. In CooperSurgical, the company is investing in fertility and women’s health offerings, including devices, donor gametes, and storage services, to broaden its clinical platform and deepen relationships with providers. Management also continues to spend on R&D for contact lens technology, manufacturing process improvements, surgical devices, and fertility solutions, which supports product differentiation and manufacturing efficiency. The company uses a mix of direct sales, distributors, digital marketing, and professional education to reach practitioners and clinics across markets of different sizes.

- **Expand specialty contact lenses and myopia management** (short-term) — These products support higher-value recurring demand and differentiate CooperVision from commodity lens competitors.
- **Build CooperSurgical’s fertility and women’s health platform** (medium-term) — A broader clinical offering increases cross-selling opportunities and deepens relationships with fertility clinics and hospitals.
- **Improve manufacturing and supply resilience** (medium-term) — The company relies on approved sites and specialized materials, so process improvements and redundancy reduce disruption risk.

- Grow premium silicone hydrogel and specialty lens categories
- Expand myopia-management adoption through MiSight and awareness campaigns
- Broaden CooperSurgical’s fertility and women’s health platform
- Invest in R&D and manufacturing process enhancements
- Use direct sales, distributors, and digital channels to widen reach
- Defend intellectual property and brand position in global markets

## Risks

Cooper faces operational risk from dependence on specialized manufacturing sites and approved production lines, especially for certain lenses and media products that cannot be quickly replaced if a facility is disrupted. The company also faces supply-chain risk from raw materials and components used in silicone hydrogel lenses, which can affect production and margins. Customer consolidation is increasing in both CooperVision and CooperSurgical, so the loss or repricing pressure from a few large retail chains or key account groups could have a disproportionate effect. Demand is exposed to healthcare utilization patterns, seasonality, inflation, foreign exchange, and regulatory changes across many jurisdictions, while cybersecurity and third-party technology failures could interrupt operations or expose confidential data. As a medical device company, Cooper also faces ongoing product quality, reimbursement, and compliance risks typical of regulated healthcare markets.

- **Manufacturing disruption at approved sites** [high] — Some products are made at only one approved facility, so downtime can cause lost sales and require lengthy regulatory revalidation.
- **Raw material and component shortages** [high] — Silicone hydrogel lens production depends on specialized inputs that may be difficult to source quickly.
- **Customer concentration from market consolidation** [medium] — Fewer, larger retail and key-account customers can increase bargaining power and revenue concentration.
- **Cybersecurity and third-party technology failure** [high] — A successful attack or vendor outage could interrupt manufacturing, distribution, or financial reporting systems.
- **Foreign exchange and inflation pressure** [medium] — International sales and global manufacturing expose the company to currency swings and rising labor/input costs.

- Single-site or limited-site manufacturing can prolong recovery after disruption
- Silicone hydrogel raw material shortages can constrain lens output
- Large customer consolidation increases key-account concentration risk
- Seasonality lowers first-quarter sales in both segments
- FX volatility affects reported sales and manufacturing costs
- Cybersecurity or third-party IT failures could disrupt operations and data
- Regulatory and reimbursement changes can affect product access and demand

## Accounting

Revenue recognition is a key accounting area because Cooper sells both products and services, and revenue is recognized when control transfers or services are rendered. The company records rebates, sales incentives, volume discounts, contractual pricing allowances, and product returns as variable consideration, so estimates can affect reported net sales and margins. CooperSurgical’s Medicaid-related rebates require judgment because reimbursement timing can lag the original sale, creating estimation risk in accruals. Seasonality also matters: first-quarter sales are typically lower because patient traffic to practitioners, fertility clinics, and surgery centers falls during the holiday period, which can distort quarterly comparisons. Business combinations, acquired intangibles, and goodwill are important because the company routinely acquires businesses and uses fair-value estimates that can later affect amortization and impairment charges.

- **Variable consideration in revenue recognition** — Net sales and gross margin
- **Medicaid rebate accruals** — Revenue, receivables, and accrual liabilities
- **Seasonality in quarterly results** — Quarterly revenue and operating income
- **Acquisition accounting and intangible amortization** — Operating income and balance sheet carrying values
- **Goodwill impairment risk** — Non-cash impairment charges

- Revenue is recognized when control transfers or services are rendered
- Rebates, discounts, incentives, and returns reduce net sales through estimates
- Medicaid rebate accruals in CooperSurgical require judgment and trend analysis
- First-quarter seasonality affects comparability across quarters
- Acquired intangibles and goodwill depend on valuation assumptions
- Business combinations can create future amortization and impairment risk

---

*Last updated: 2026-09-24T12:21:56.050556+00:00*